UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~WASHINGTON~~Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to to Section 13 orOR 15 (d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 26, 2019

~~January~~Scivanta 4,Medical ~~2016~~Corporation

~~SCIVANTA~~(Exact name of registrant as specified in ~~MEDICAL~~its ~~CORPORATION~~charter)

(Exact name of registrant as specified in charter)

Nevada		000-27119		22-2436721
(state or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

Nevada		000-27119		22-2436721
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

215 Morris Avenue, Spring Lake, New Jersey 07762

215 Morris Avenue, Spring Lake, New Jersey		07762
(Address of principal executive offices)		(Zip Code)

(address of principal executive offices) (zip code)

~~Registrant’s telephone number, including area code:~~ (732) 282-1620

(~~Former name~~registrant’s ortelephone ~~former address~~number, ifincluding area ~~changed since last report~~code)

(former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Section 3~~Emerging –growth ~~Securities~~company ~~and Trading Markets~~x

~~Item~~If ~~3.02.~~an ~~Unregistered~~emerging ~~Sales~~growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of ~~Equity~~the ~~Securities~~Exchange Act. ¨

~~On January~~Item ~~4, 2016, Scivanta Medical Corporation (the “Company”) issued a 10% convertible debenture to an individual investor (the “Debenture”)~~5.02 InDeparture ~~connection with the issuance~~ of ~~the~~Directors ~~Debenture,~~or ~~the~~Certain ~~Company~~Officers; ~~issued~~Election ~~a warrant (the “Debenture Warrant”) to purchase shares~~ of ~~its~~Directors; ~~common~~Appointment ~~stock equal to 20%~~ of ~~the~~Certain ~~aggregate~~Officers; ~~principal~~Compensatory ~~amount~~Arrangements of ~~the~~Certain Debenture. The gross proceeds received in connection with this private placement were $50,000. The Debenture has a one-year term with principal and interest due on January 4, 2017. The Debenture bears interest at a rate of 10% per annum.Officers

~~The~~On ~~entire~~April ~~principal~~26, ~~and~~2018, ~~accrued~~the ~~interest~~Board of ~~the~~Directors ~~Debenture is convertible into shares~~ of the ~~Company’s~~registrant ~~common~~accepted ~~stock (a) upon~~ the ~~Company~~resignation ~~issuing equity securities and/or debt in a transaction or a series~~ of ~~transactions~~Thomas ~~resulting~~Gifford inas ~~aggregate~~President ~~gross~~and ~~proceeds to the Company of at least $3,000,000 (~~a ~~“Qualified Financing”); (b) at the option of the holder, at the maturity~~member ~~date~~ of the ~~Debenture;~~registrant’s orBoard ~~(c) at the option~~ of ~~the~~Directors ~~holder,~~and ~~upon~~appointed aLeonard ~~Change~~Lovallo ~~in Control of the Company,~~ as ~~defined in the Debenture~~President. ~~Upon~~ ~~the~~Leonard ~~occurrence~~Lovallo, ~~of a Qualified Financing~~37, ~~the Debenture~~ is ~~convertible~~Managing ~~into shares~~ Member of ~~the~~Millennial ~~Company’s~~Investments, ~~common~~LLC, ~~stock at~~ a ~~conversion~~consulting ~~price~~firm ~~equal~~that ~~to:~~he ~~(i)~~controls, ~~80%~~through ofwhich ~~the~~he ~~per~~has, ~~share~~since ~~price~~2014, ~~paid~~assisted bypublic ~~the~~and ~~purchasers~~private companies ~~of the Company’s common stock~~ in the ~~Qualified~~ ~~Financing;~~areas ~~(ii) 80%~~ of ~~the~~mergers, ~~per~~acquisitions, ~~share~~debt ~~conversion~~restructuring, ~~price~~equity ofinvestments ~~any~~and ~~instrument~~corporate ~~convertible~~governance. ~~into~~Mr. ~~shares~~Lovallo graduated offrom the ~~Company’s common~~State ~~stock,~~University ~~if no shares~~ of ~~the~~New ~~Company’s~~York ~~common stock are issued in the Qualified Financing; or~~ (~~iii~~Buffalo) ~~$0.065,~~with ifa noBA ~~shares of the Company’s common stock or instruments convertible into shares of the Company’s common stock are issued~~ in ~~the Qualified Financing~~psychology. OnIn ~~the~~connection ~~maturity~~with ~~date~~his orbeing ~~upon~~appointed aas ~~Change in Control~~ President of the ~~Company~~registrant ~~the~~Mr. ~~Debenture~~Lovallo is ~~convertible~~receiving ~~into~~500,000 shares of ~~the Company’s common stock at $0.065 per share. The quoted market price~~ of the ~~Company~~registrant’s common stock ~~on January 4~~, ~~2016~~an ~~was~~award ~~$0.025 per share. An aggregate~~ of ~~769~~1,~~230~~000,000 shares upon of the ~~Company’s~~registrant ~~common~~becoming ~~stock~~current ~~can~~in beits ~~issued~~SEC ~~pursuant~~filings toand ~~the Debenture~~a atsalary ~~the current conversion price~~ of $~~0.065~~2,000 per ~~share~~month. ~~The Company will use the proceeds received in this private placement for working capital purposes.~~

The Debenture Warrant has a three-year term and provides the holder the right to purchase shares of the Company’s common stock equal to 20% of the principal amount of the related Debenture divided by: (a) 80% of the per share price paid by the purchasers of the Company’s common stock in a Qualified Financing; (b) 80% of the per share conversion price of any instrument convertible into shares of the Company’s common stock issued in a Qualified Financing, if no shares of the Company’s common stock are issued in the Qualified Financing; or (c) $0.065, if no shares of the Company’s common stock or no instruments convertible into shares of the Company’s common stock are issued in a Qualified Financing or if a Qualified Financing is not consummated within one year from the Debenture Warrant issuance date. An aggregate of 153,846 shares of the Company’s common stock can be issued under the Debenture Warrant at the current exercise price of $0.065 per share. All of the shares of the Company’s common stock underlying the Debenture Warrant vests on the earlier of (a) one year from the Debenture Warrant issuance date, or (b) the consummation of a Qualified Financing. The exercise price of the Debenture Warrant will be subject to adjustment for stock dividends, stock splits, or similar events.2

In connection with the issuance of the Debenture, the Company relied on the exemption from registration for a private transaction not involving a public distribution provided by Section 4(2) of the Securities Act of 1933, as amended.SIGNATURES

~~Section~~Pursuant 9to –the ~~Financial~~requirements ~~Statements~~of ~~and~~the ~~Exhibits~~Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Item 9.01. Financial Statements and Exhibits.

Date: April 30, 2019	Scivanta Medical Corporation

	By:	/s/ Leonard Lovallo
		Name: Leonard Lovallo
		Title: President

~~(d) Exhibits:~~3

Exhibit

	Exhibit Number		Description
	4.1		Form of 10% Convertible Debenture (incorporated by reference to Exhibit 4.1 to the Company’s current report on Form 8-K filed with the Securities and Exchange Commission on December 17, 2013).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SCIVANTA MEDICAL CORPORATION (Registrant) By: /s/ David R. LaVance David R. LaVance President and Chief Executive Officer

Date: January 7, 2015

EXHIBIT INDEX

Exhibit Number		Description
4.1		Form of 10% Convertible Debenture (incorporated by reference to Exhibit 4.1 to the Company’s current report on Form 8-K filed with the Securities and Exchange Commission on December 17, 2013).

Filing Compare · SCIVANTA MEDICAL CORP